FDA applicant
Horiba Abx
FDA records 37 decisions for Horiba Abx (Montpellier, FR) from 2005 to 2026: 37 510(k) clearances. Most are in product codes GKZ (Counter, Differential Cell) and DCK (C-Reactive Protein, Antigen, Antiserum, And…). Since 2016 its 510(k)s took a median of 244 days from receipt to decision, against 254 for FDA’s reviews in the same codes and years. Its devices cite 95 predicates, 20 of them its own earlier devices. 21 recalls are linked to its devices.
FDA’s records also spell it “HORIBA ABX SAS”.
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly
How often FDA has decided Horiba Abx’s devices, and how often a recall has named them.
FDA decisions per year
1in 2024
2026 so far, outlined.
Recalls per year
1in 2022
Class I Class II/III not classified
Planning a device like Horiba Abx’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.
See the 510(k) ReportOther applicant names beginning “Horiba”
FDA records each applicant name separately; these may or may not be the same firm.